Article
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer biology & therapy - 1 Jan 2000
Ando Yuichi, Price Douglas K, Dahut William L, Cox Michael C, Reed Eddie, Figg William D
Abstract excerpt
Thalidomide requires cytochrome P450 (CYP)-catalyzed biotransformation for its antiangiogenic property, and CYP2C19 is responsible for 5-hydroxylation and 5'-hydroxylation of thalidomide in human. This study explored a hypothesis that patients with poor metabolizing phenotype of CYP2C19 receive little benefit from thalidomide treatment and that the poor metabolizer genotype is associated with lower ability to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.